文献速递产科母胎医学

存在胎儿新生儿同种免疫性血小板减少症(FNAIT)风险的妊娠的产前管理:科学影响论文第61号

Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61.
PubMed 文献 · BJOG · 2019-04-09

本文讨论存在胎儿新生儿同种免疫性血小板减少症(FNAIT)风险的妊娠的处理,包括筛查的作用、静脉注射免疫球蛋白(IVIg)的起始时机与剂量、母体使用类固醇的证据,以及极罕见情况下胎儿血液采样和产前给胎儿输注血小板。文章还涉及部分国家提供的母体血液检测方法及降低FNAIT风险的新疗法开发。

要点

  • FNAIT由母体抗HPA抗体经胎盘攻击胎儿血小板所致,最常见为抗HPA-1a。
  • 因疾病罕见且无法预测胎儿受累严重程度,目前不推荐常规筛查。
  • 对大多数病例,静脉注射免疫球蛋白(IVIg)是有效治疗。

核心结论

  • 本文综述了FNAIT风险妊娠治疗选择的最新证据,涵盖筛查作用、IVIg起始时机与剂量、母体类固醇证据,以及极罕见病例中胎儿血液采样和产前胎儿血小板输注。
  • 文章还讨论了部分国家提供的母体血液检测方法及降低FNAIT风险的新疗法开发。

研究设计与样本

  • 本文为科学影响论文(Scientific Impact Paper No. 61),由皇家学院(Royal College)发布,讨论FNAIT风险妊娠管理的最新证据。

主要发现

  • 在英国,每周可能有一名婴儿受到严重影响,较轻形式可影响每1000例出生中的1例。
  • 最常见的抗体为抗HPA-1a,但存在其他更罕见的抗体类型。
  • 若血小板计数极低,胎儿在出生前有脑出血风险,这种情况非常罕见但一旦发生可对婴儿健康造成严重影响。
  • FNAIT通常在既往婴儿有血小板计数低时被诊断,父母接受血液检测以确认或排除该病。
  • 因疾病非常罕见,专业知识限于专科中心,通常由血液科医生和胎儿医学医生共同进行和解读检测。

关键数值与推荐

  • 对大多数病例,有效治疗为免疫球蛋白(IVIg),通过静脉滴注每周给予有风险的孕妇。
  • IVIg可在下次妊娠最早16周开始,直至分娩,分娩约在36-37周提供。
  • 较少见的治疗可根据个体情况考虑,包括类固醇片剂或注射,或给婴儿输注血小板。
  • 因疾病非常罕见且即使婴儿有风险也无法知道受累严重程度,目前不推荐常规筛查。

临床怎么用

  • FNAIT通常在既往婴儿有血小板计数低时被诊断,父母接受血液检测以确认或排除该病,并可能需检测其他导致婴儿血小板低的原因。
  • 有FNAIT风险的孕妇可接受IVIg静脉滴注,每周一次,最早从16周开始至分娩,分娩约在36-37周。
  • 较少见的治疗可根据个体情况考虑,包括类固醇片剂或注射,或给婴儿输注血小板。
  • 极罕见 selected 病例中可考虑胎儿血液采样和产前给胎儿输注血小板。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

WHAT IS IT?: Fetal neonatal alloimmune thrombocytopenia (FNAIT), also known as neonatal alloimmune thrombocytopenia (NAIT) or fetomaternal alloimmune thrombocytopenia (FMAIT), is a rare condition which affects a baby's platelets. This can put them at risk of problems with bleeding, particularly into the brain. One baby per week in the UK may be seriously affected and milder forms can affect one in every 1000 births. HOW IS IT CAUSED?: Platelets are blood cells that are very important in helping blood to clot. All platelets have natural proteins on their surface called human platelet antigens (HPAs). In babies, half of these antigens are inherited from the mother and half from the father. During pregnancy, some of the baby's platelets can cross into the mother's bloodstream. In most cases, this does not cause a problem. But in cases of FNAIT, the mother's immune system does not recognise the baby's HPAs that were inherited from the father and develops antibodies, which can cross the placenta and attack the baby's platelets. These antibodies are called anti-HPAs, and the commonest antibody implicated is anti-HPA-1a, but there are other rarer antibody types. If this happens, the baby's platelets may be destroyed causing their platelet count to fall dangerously low. If the platelet count is very low there is a risk to the baby of bleeding into their brain before they are born. This is very rare but if it happens it can have serious effects on the baby's health. HOW IS IT INHERITED?: A baby inherits half of their HPAs from its mother and half from its father. Consequently, a baby may have different HPAs from its mother. As the condition is very rare, and even if the baby is at risk of the condition we have no way of knowing how severely they will be affected, routine screening is not currently recommended. WHAT CAN BE DONE?: FNAIT is usually diagnosed if a previous baby has had a low platelet count. The parents are offered blood tests and the condition can be confirmed or ruled out. There are many other causes of low platelets in babies, which may also need to be tested for. As the condition is so rare, expertise is limited to specialist centres and normally a haematologist and fetal medicine doctor will perform and interpret the tests together. Fortunately, there is an effective treatment for the vast majority of cases called immunoglobulin, or IVIg. This 'blood product' is given intravenously through a drip every week to women at risk of the condition. It may be started from as early as 16 weeks in the next pregnancy, until birth, which would be offered at around 36-37 weeks. Less common treatments that may be considered depending on individual circumstances include steroid tablets or injections, or giving platelet transfusions to the baby. WHAT DOES THIS PAPER TELL YOU?: This paper considers the latest evidence in relation to treatment options in the management of pregnancies at risk of FNAIT. Specifically, we discuss the role of screening, when IVIg should be started, what dose should be used, and what evidence there is for maternal steroids. We also consider in very rare selected cases, the use of fetal blood sampling and giving platelet transfusions to the baby before birth. Finally, we consider the approaches to blood testing mothers to tell if babies are at risk, which is offered in some countries, and development of new treatments to reduce the risk of FNAIT.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Regan F, Lees CC, Jones B, et al. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61. BJOG. 2019. PMID: 30968555. doi:10.1111/1471-0528.15642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。